• KOL
    • Dendritic Cells
    • Cornelis Joseph Melief
    • Cornelis Joseph Melief: Influence Statistics

      Cornelis Joseph Melief

      Cornelis Joseph Melief

      Show email address

      ISA Pharmaceuticals, Leiden, The Netherlands | Department of Immunology, Leiden University Medical Center, Leiden, Netherlands | ISA Pharmaceuticals BV, Leiden, the ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Cornelis Joseph Melief:Expert Impact

      Concepts for whichCornelis Joseph Meliefhas direct influence:Dendritic cells,Mhc class,Human papillomavirus,Tumor cells,Hla class,Cervical cancer.

      Cornelis Joseph Melief:KOL impact

      Concepts related to the work of other authors for whichfor which Cornelis Joseph Melief has influence:Dendritic cells,Mhc class,Cancer immunotherapy,Extracellular vesicles,Immune response,Human papillomavirus,Tumor microenvironment.

      KOL Resume for Cornelis Joseph Melief

      Year
      2022

      ISA Pharmaceuticals, Leiden, The Netherlands

      2020

      Department of Immunology, Leiden University Medical Center, Leiden, Netherlands

      2019

      ISA Pharmaceuticals, Leiden, the Netherlands.

      2018

      Department of Immunohematology and Blood Transfusion, section Tumorimmunology, Leiden University Medical Center, Leiden, The Netherlands

      2017

      Department of Immunohematology Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

      ISA Pharmaceuticals, Leiden

      2016

      Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. ISA Pharmaceuticals, Leiden, the Netherlands.

      Leiden University Medical Center, Leiden, Netherlands;

      2015

      Leiden University; ISA Pharmaceuticals , Netherlands.

      2014

      Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands

      2013

      Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands, ISA Pharmaceuticals, Leiden, the Netherlands.

      Leiden University Medical Center and ISA Pharmaceuticals, Leiden, The Netherlands

      2012

      Immune System Activation, Leiden University Medical Center, Leiden, The Netherlands.

      Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands

      2011

      Departments of Immunohematology and Blood Transfusion, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

      2010

      Department of Immunohematology and Blood Transfusion, Leiden, the Netherlands

      2009

      Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands

      2008

      Department of Immunohematology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands

      2007

      Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Cornelis Joseph Melief is among the top experts in the world.
      Concept World rank
      regulation pa28alphabeta expression #1
      efficient peptidemhc class #1
      single residue exchange #1
      e7‐specific cd4 #1
      viral epitopes genome #1
      neoplastic cells patients #1
      patients marker analysis #1
      abl hla #1
      bm12 type nonresponder #1
      presentation hel protein #1
      129 mice susceptibility #1
      tlr2ligand conjugation #1
      hlaa3 assays #1
      fusion glycoprotein mvf #1
      pamsconjugate #1
      susceptibility 129 mice #1
      h–2a #1
      dbm13 molecule #1
      immunologic cytotoxicity immunity #1
      conserved adenovirus #1
      immunotherapy pegintron #1
      sllqhligl #1
      delayed oncogene proteins #1
      lymphomas viral antigens #1
      encoded ctl #1
      stem cells gvhr #1
      clade a9 #1
      mhc mutant mouse #1
      extended ctl peptides #1
      synthetic artificial infections #1
      immunoglobulin synthesis interleukin #1
      heterologous vaccine modalities #1
      mechanisms effective immunity #1
      helper immunity #1
      t‐cell‐receptor diversity #1
      t‐cell tumors #1
      ctl kbtransgenic transgenic #1
      hiv1 hivconsv #1
      uchl1 keratinocytes #1
      p53‐specific #1
      nuclear p53 oncogenicity #1
      thath2bg1h2bg2 #1
      increased gag expression #1
      prame target #1
      lymphoid organs maturation #1
      ecotropic isolates #1
      derived form autoantigens #1
      animal female lymphocytes #1
      acute gvhd signs #1
      toregulate #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Cornelis Joseph Melief

      KOL-Index: 18499

      PURPOSE: The study aims to evaluate the effect of a human papillomavirus type 16 (HPV16) E6 and E7 synthetic long peptides vaccine on the antigen-specific T-cell response in cervical cancer patients.

      EXPERIMENTAL DESIGN: Patients with resected HPV16-positive cervical cancer were vaccinated with an overlapping set of long peptides comprising the sequences of the HPV16 E6 and E7 oncoproteins emulsified in Montanide ISA-51. HPV16-specific T-cell immune responses were analyzed by evaluating ...

      Known for Long Peptides | Specific Cd4 | Papillomavirus Type | Hpv16 E6 | Cervical Cancer
      KOL-Index: 17282

      The in vivo importance of class I MHC regulation of the Tc response to a natural pathogenic agent of high virulence was studied on the basis of our previous demonstration of a major difference in the capacity to generate a Sendai virus-specific Tc response between C57BL/6 (B6, H-2b) mice and H-2Kb mutant B6.C-H-2bm1 (bm 1) mice. These two mouse strains differ from each other only in three amino acids in the crucial H-2Kb restriction element for this response. bm 1 mice, in contrast to B6 ...

      Known for Sendai Virus | B6 Mice | Lethal Dose | Clones Mixture | Cytotoxic Tlymphocytes
      KOL-Index: 15204

      INTRODUCTION: Ewing sarcoma (EWS) is a malignant bone-associated sarcoma, with poor prognosis in case of metastasis or relapse. To explore the feasibility of natural killer (NK) cell mediated immunotherapy and to identify molecular mechanisms involved, the susceptibility of EWS to NK cells was investigated.

      METHODS AND RESULTS: All EWS cell lines tested (n=7) were lysed by purified allogeneic NK cells from healthy donors, and the efficacy of lysis was increased by activating NK cells ...

      Known for Nk Cells | Ewing Sarcoma | Cell Cytotoxicity | Dnam1 Receptor | Healthy Donors
      KOL-Index: 14117

      Athymic H-2b nude mice received grafts from C57BL/6 (Sendai virus and H-Y antigen cytotoxic T lymphocyte [CTL] responder type), bm1 (H-2Kb mutant, Sendai CTL nonresponder type), or bm12 (H-21-A mutant, H-Y CTL nonresponder type) neonates. In observations of the CTL response to H-Y, both recipients and thymus donors were female. All types of thymus engraftment resulted in mature H-2b splenic T lymphocyte surface phenotype in nude hosts. T cell immunocompetence (as measured by major ...

      Known for Major Histocompatibility | Inbred Balb Mice | Sendai Virus | Ctl Response | Mhc Class
      KOL-Index: 14012

      The antigen processing-defective mutant cell line RMA-S expresses at the cell surface major histocompatibility complex (MHC) class I molecules devoid of peptide that can be efficiently loaded with exogenous immunogenic peptides. We now report that viral peptide-loaded RMA-S cells, unlike parental RMA cells, can induce primary cytotoxic T lymphocyte (CTL) responses in vitro, in a T helper cell-independent fashion. This was shown for an H-2Kb-binding peptide of Sendai virus nucleoprotein ...

      Known for Histocompatibility Complex | Rma Cells | Lymphocyte Responses | Primary Cytotoxic | Mhc Class
      KOL-Index: 13693

      PURPOSE: To determine the toxicity, safety, and immunogenicity of a human papillomavirus 16 (HPV16) E6 and E7 long peptide vaccine administered to end-stage cervical cancer patients.

      EXPERIMENTAL DESIGN: Three groups of end-stage cervical cancer patients (in total n = 35) were s.c. vaccinated with HPV16 E6 combined with or separated from HPV16 E7 overlapping long peptides in Montanide ISA-51 adjuvant, four times at 3-week intervals. Group 1 received 300 microg/peptide at a single site ...

      Known for Long Peptides | Human Papillomavirus | Cervical Cancer | Hpv16 E6 | Safety Toxicity
      KOL-Index: 13403

      Peptide-based vaccines aimed at the induction of effective T cell responses against established cancers have so far only met with limited clinical success and clearly need to be improved. In a preclinical model of human papillomavirus (HPV)16-induced cervical cancer we show that prime-boost vaccinations with the HPV16-derived 35 amino-acid long peptide E7(43-77), containing both a CTL epitope and a Th epitope, resulted in the induction of far more robust E7-specific CD8(+) T cell ...

      Known for Long Peptide | Animal Epitopes | Human Papillomavirus | Transformed Cells | Oncogene Proteins
      KOL-Index: 13265

      Despite sufficient levels of HLA class I and class II expression, acute myeloid leukemia (AML) cells usually fail to induce a significant T-cell response in vitro. Therefore, we investigated whether in vitro modifications could enhance the T-cell stimulatory properties of AML cells. AML cells were either cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and tumor necrosis factor-alpha (TNF-alpha), or transfected with the CD80 (B7.1) gene and ...

      Known for Leukemia Cells | Acute Myeloid | Histocompatibility Antigens | Patient Leukemic | Cd80 Aml
      KOL-Index: 13148

      A peptide-binding assay employing the HLA class I molecules on intact human B cells is described. The peptide antigens are stripped from the HLA class I molecules by mild acid treatment, after which the cells are incubated with a FL-labeled reference peptide together with different concentrations of the peptide of interest. The effectiveness by which the latter peptide competes for binding to the HLA class I molecules is assayed by measuring the amount of HLA-bound FL-labeled reference ...

      Known for Hla Class | Binding Assay | Peptide Antigens | Ctl Epitopes | Sequence Lymphocytes
      KOL-Index: 13079

      This study shows that induction of tumor-specific CD4+ T cells by vaccination with a specific viral T helper epitope, contained within a synthetic peptide, results in protective immunity against major histocompatibility complex (MHC) class II negative, virus-induced tumor cells. Protection was also induced against sarcoma induction by acutely transforming retrovirus. In contrast, no protective immunity was induced by vaccination with an unrelated T helper epitope. By cytokine pattern ...

      Known for Optimal Induction | Helper Cells | Cytotoxic Tlymphocytes | Protective Immunity | Major Histocompatibility

      Key People For Dendritic Cells

      Top KOLs in the world
      #1
      Ralph Marvin Steinman
      dendritic cells inbred balb mice antigen presentation
      #2
      Jacques F Banchereau
      dendritic cells somatic mutation metastatic melanoma
      #3
      Antonio Lanzavecchia
      dendritic cells monoclonal antibodies cell activation
      #4
      YONG‐JUN LIU
      dendritic cells thymic stromal lymphopoietin allergic inflammation
      #5
      Gerold Schuler
      dendritic cells melanoma patients inbred balb mice
      #6
      Federica Sallusto
      dendritic cells monoclonal antibodies chemokine receptors

      ISA Pharmaceuticals, Leiden, The Netherlands | Department of Immunology, Leiden University Medical Center, Leiden, Netherlands | ISA Pharmaceuticals BV, Leiden, the Netherlands. | Department of Immunohematology and Blood Transfusion, Leiden Universit

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.